Jove
Visualize
联系我们

相关概念视频

Clinical Trials: Overview01:11

Clinical Trials: Overview

4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K
Clinical Trials01:16

Clinical Trials

10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.1K
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

144
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
144
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

227
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
227
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

407
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
407
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.3K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.3K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Morphologic evaluation in fibrotic hypersensitivity pneumonitis: the era of quantitative CT is upon us.

Annals of the American Thoracic Society·2026
Same author

Progressive pulmonary fibrosis: a state-of-the-art review.

The European respiratory journal·2026
Same author

Assessment of noninvasive parameters prior to diagnosis of pulmonary hypertension in patients with fibrotic interstitial lung disease.

ERJ open research·2026
Same author

Changes in Interstitial Lung Disease Nomenclature.

Archivos de bronconeumologia·2026
Same author

Response.

Chest·2026
Same author

A statistical model for lung function trajectory and mortality in patients with fibrotic interstitial lung disease.

American journal of respiratory and critical care medicine·2026
Same journal

Clinical remission in elderly patients with sarcoidosis.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2026
Same journal

A case of a rapidly progressing, recurrent orbital mass.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2026
Same journal

Composite Inflammatory Indices for the Differentiation of Tuberculosis, Sarcoidosis, and Reactive Lymphadenopathy in Patients Undergoing EBUS-TBNA.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2026
Same journal

Supervised Home-Based Telerehabilitation for Idiopathic Pulmonary Fibrosis: A Pragmatic Service Evaluation in Routine Care with Detraining Follow-up.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2026
Same journal

Transcriptomic profiling of collagen gene expression in lung fibroblasts from patients with idiopathic pulmonary fibrosis.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2026
Same journal

Unveiling novel susceptibility genes for sarcoidosis by a cross-tissue transcriptome-wide association study.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2026
查看所有相关文章
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关实验视频

Updated: Jan 16, 2026

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
08:33

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Published on: January 5, 2024

1.6K

临床试验终点工作组:执行总结

Robert P Baughman1, Elyse E Lower2, Daniel A Culver3

  • 1Editor-in-chief, Sarcoidosis, Vasculitis and Diffuse Lung Diseases; University of Cincinnati, Department of Medicine, Cincinnati, OH, USA.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG
|September 30, 2025
PubMed
概括
此摘要是机器生成的。

新的指导方针涉及肺部和心脏型硬化症的临床试验终点. 世界沙丘病和其他粒状瘤疾病协会 (WASOG) 工作组为未来的研究制定了十三份认可声明.

更多相关视频

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.1K
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.5K

相关实验视频

Last Updated: Jan 16, 2026

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
08:33

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Published on: January 5, 2024

1.6K
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.1K
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.5K

科学领域:

  • 肺部病理学 肺部病理学
  • 心脏病学 心脏病学
  • 类风湿病学 类风湿病学
  • 临床试验 临床试验

背景情况:

  • 肺部和心脏样症的临床试验缺乏标准化的终点.
  • 上一篇:世界沙丘病和其他粒状瘤疾病协会 (WASOG) 的指导方针于2011年建立.
  • 越来越需要更新关于试验终点的共识.

研究的目的:

  • 更新2011年WASOG临床试验终点指南.
  • 建立关于肺部和心脏类病临床试验的适当终点的共识.
  • 为了反映在 Sarcoidosis 研究的最新进展和专家意见.

主要方法:

  • 在2024年组建WASOG临床试验终点工作组.
  • 涉及55个利益相关者:医疗保健提供者,行业代表和患者.
  • 这次为期一天的会议共有46名与会者,以及20个关于试验终点的专题演讲.
  • 汇编摘要,收集反,并对已开发的陈述进行匿名投票.

主要成果:

  • 大多数利益相关者认可了13个特定的临床试验终点陈述.
  • 两个陈述集中在整体试验设计上.
  • 七个陈述涉及肺癌样症终点.七个陈述涉及肺癌样症终点.
  • 四个陈述重点关注心脏 Sarcoidosis 的终点.

结论:

  • 更新后的WASOG指导方针提供了关于型硬化症临床试验关键终点的共识.
  • 这些终点将有助于标准化未来的肺部和心脏沙尔科病的研究.
  • 认可的声明旨在改善临床试验的设计和可比性.